DiaMedica Therapeutics Inc. raised $11.8 million in a private placement to fund clinical and product development activities for DM199 and for other working capital and general corporate purposes.
Amount Raised
$11.8 Million
Round Type
Post-IPO Equity
MinneapolisBiotechnologyHealth CareTherapeuticsBiopharmaDescription
DiaMedica Therapeutics Inc. has entered into definitive agreements to sell its common shares in a private placement with accredited investors. The transaction is expected to result in gross proceeds of $11.8 million. The company plans to use the net proceeds to continue its clinical and product development activities for DM199 (rinvecalinase alfa), including its pivotal Phase 2/3 ReMEDy2 trial for the treatment of acute ischemic stroke and its clinical expansion into preeclampsia, and for other working capital and general corporate purposes.
Who to call at DiaMedica Therapeutics, and when
A new round usually means DiaMedica Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day DiaMedica Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at DiaMedica Therapeutics, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment DiaMedica Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
DiaMedica Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.